Aquestive Therapeutics to Present Anaphylm™ Data at 2024 Eastern Allergy Conference

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on enhancing patient lives through innovative science and delivery technologies, announced two encore poster presentations on Anaphylm™ (epinephrine) sublingual film at the Eastern Allergy Conference (EAC). The conference will occur from May 30 to June 2, 2024, in Palm Beach, Florida, and will feature leading experts in Allergy, Asthma, and Immunology.

Anaphylm is Aquestive's pioneering orally administered epinephrine prodrug product aimed at treating severe allergic reactions, including anaphylaxis. Dan Barber, President and CEO of Aquestive, expressed satisfaction in presenting their clinical trial results at such a prestigious conference. He emphasized Anaphylm's potential to transform severe allergy treatments and mentioned the successful completion of the Phase 3 pivotal trial. The company aims to submit an Anaphylm New Drug Application (NDA) to the FDA by the end of 2024 following additional pre-submission studies.

The first poster, titled "Epinephrine Administered via Sublingual Film, Manual Injection, or Auto-Injectors in Healthy Adults: Pharmacodynamic Results," will be presented on Friday, May 31, from 9:45-11am by lead author Dr. Gary Slatko. The second poster, "Pharmacokinetics and Pharmacodynamics of Epinephrine Following Administration via Sublingual Film, Autoinjector, or Manual Injection," will also be presented during the same time slot by lead author Dr. David Golden. These posters have previously been showcased at the American Academy of Allergy, Asthma & Immunology Annual Meeting and the American College of Allergy, Asthma & Immunology Annual Meeting and can be accessed on the Company's website.

Anaphylm is a polymer matrix-based epinephrine prodrug candidate designed for ease of use, resembling the size of a postage stamp and dissolving upon contact without the need for water or swallowing. Its compact packaging is weather-resistant and can be conveniently carried in a pocket. The U.S. Food and Drug Administration (FDA) has conditionally approved the tradename "Anaphylm" for AQST-109, pending final product approval.

Aquestive Therapeutics continues to leverage its innovative delivery technologies to develop orally administered products that offer alternatives to invasive and inconvenient standard therapies. The company currently has five commercialized products marketed by licensees globally and manufactures these licensed products exclusively. Collaborating with other pharmaceutical companies, Aquestive uses its proprietary technologies like PharmFilm® to bring new molecules to market. The company is advancing its late-stage proprietary product pipeline focused on central nervous system diseases and an earlier stage pipeline targeting severe allergic reactions, including anaphylaxis.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!